Cephalon Will Pursue New Gabitril Uses After Acquisition Of Anti-Epileptic
Executive Summary
Cephalon plans to develop Gabitril for indications outside of epilepsy, the company said after announcing the acquisition of the product from Abbott Nov. 1.
You may also be interested in...
Gabitril Potential In Anxiety Aided By Positive Side Effect Profile – Cephalon
Cephalon hopes to market the anti-epileptic Gabitril (tiagabine) for generalized anxiety disorder by 2006 based on a favorable side effect profile
Gabitril Potential In Anxiety Aided By Positive Side Effect Profile – Cephalon
Cephalon hopes to market the anti-epileptic Gabitril (tiagabine) for generalized anxiety disorder by 2006 based on a favorable side effect profile
Gabitril label change
Cephalon is removing Filmtab from Gabitril (tiagabine) label because name of the tablet coating process is trademarked by Abbott. Change only pertains to product name; manufacturing process for the antiepileptic drug has not changed, Cephalon says in Aug. 27 "Dear Healthcare Professional" letter. Cephalon purchased Gabitril from Abbott in November 2000 (1"The Pink Sheet" Nov. 6, 2000, p. 9)